Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-11-08
2010-12-28
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C514S009100
Reexamination Certificate
active
07858577
ABSTRACT:
The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.
REFERENCES:
patent: 5426181 (1995-06-01), Lee et al.
patent: 99/32516 (1999-07-01), None
patent: WO 9932516 (1999-07-01), None
Janeway, Immunobiology, third edition, 1997, Garland Publishing Inc., p. G1.
Benharroch et al., Isr J Med Sci, 1990, 26:212-219.
Jackson et al., Molecular and Cellular Endocrinology, 2006, 247:183-191.
Korah et al., Cancer Research, 2000, 60:733-740.
Luchetti et al., Clin Exp Immunol 2000, 119:196-202.
Rolph et al., Arterioscler Thomb Vasc Biol 2002, 22:1-5.
Givol et al., FASEB J., 1992, 6:3362-3369.
Dionne et al., EMBO J., 1990, 9:2685-2692.
Pels et al., Jnp. Circ. J., 1997, 61:893-904.
Gewurz et al., Curr. Opin. Immunol., 1995, 7:54-64.
Bassi et al., Clin Rev Allergy Immunol. Nov. 18, 2008. [Epub ahead of print], 8 pages.
Bevelacqua et al., Int J Mol Med. Sep. 2006;18(3):415-23.
Kotooka et al., Atherosclerosis. Mar. 2008;197(1):368-74. Epub Jul. 19, 2007.
Souza et al., Am J Pathol. Apr. 2009;174(4):1309-18. Epub Mar. 12, 2009.
Popma et al., Am J Med. Jan. 1990;88(1N):16N-24N.
Zhang et al., J Lab Clin Med. Aug. 2002;140(2):119-25.
Post et al., Clin Cardiol. Jun. 2002;25(6):271-8.
Camozzi et al., Arterioscler Thromb Vasc Biol. Sep. 2000;25(9):1837-42. Epub Jul. 14, 2005.
Linder et al., Proc Natl Acad Sci U S A. May 1, 1991;88(9):3739-43.
Rutherford et al., Atherosclerosis. Apr. 1997;130(1-2):45-51.
Merck Manual of Diagnosis and Therapy, 17thedition, 1999, pp. 729-731.
Luchetti et al; “Expression and Production of the Long Pentraxin PTX3 in Rheumatoid Arthritis (RA)”; Clinical and Experimental Immunology, vol. 119, Jan. 2000, pp. 196-202, XP002191383.
Polentarutti et al; “Interferon-Gamma Inhibits Expression of the Long Pentraxin PTX3 in Human Monocytes”; European Journal of Immunology, vol. 28, 1998, pp. 496-501, XP002191384.
Bottazzi et al; “Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3”; The Journal of Biological Cahemistry, vol. 272, No. 52, Dec. 26, 1997, pp. 32817-32823, XP002191385.
Introna et al; “Cloning of Mouse PTX3, A New Member of the Pentraxin Gene Family Expressed at Extrahepatic Sites”; Blood, W.B. Saunders, Philadelphia, VA, US, vol. 87, No. 5, Mar. 1, 1996, pp. 1862-1872, XP002113121.
Brooks, P. et al., “Use of the 10-Day-Old Chick Embryo Model for Studying Angiogensis” Methods in Molecular Biology, vol. 129, pp. 25-269. Jul. 1999.
Ribatti, D. et al., “TheChick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis” Current Pharmaceutical Biotechnology, 2000, pp. 73-82.
Bottazzi Barbara
Mantovani Alberto
Presta Marco
Rusnati Marco
Lucas & Mercanti LLP
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Szperka Michael
LandOfFree
Use of the long pentraxin PTX3 for the treatment of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the long pentraxin PTX3 for the treatment of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the long pentraxin PTX3 for the treatment of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166878